Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Philip Murphy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $38,242 — The aim of this project is to test the hypothesis that specific chemokines and chemokine receptors drive either immunopathology or immune control of SARS-CoV-2 infection in a mouse model. The motivation for this aim is that chemokines regulate leukocyte trafficking and covid-19 disease pathogenesis …
l aravind · NATIONAL LIBRARY OF MEDICINE · 2023 · $1,162,010 — The systematic analysis and discovery of biological conflict systems has been a major focus of research in the Aravind lab. Biological replicators, from genes within a genome to whole organisms, are locked in conflicts. Comparative genomics has revealed a staggering diversity of molecular armaments …
Yasmine Belkaid · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $5,049,028 — In response to the SARS-CoV-2 pandemic we have made the advanced technologies platforms and basic and complex informatics at CHI available for characterization of COVID-19 patient samples, as a priority ahead of our ongoing collaborative studies. The CHI program contributed to two publications and a…
William Elkins · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $576,947 — COVID 19 related projects: Humanized animals: We are interested in generating humanized NOD/ShiLtJ (hNOD/ShiLtJ) mice for ACE2 gene as a common NIAID resource for underlying conditions in humans for COVID-19 research. We need to change 15 amino acids (AA) in mouse gene with human AA in exon#2 (5 mu…
Geoffrey Mueller · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2023 · $753,852 — I. Origins of Allergic Disease Nothing to report this year. II. Characterization of Allergens The NMR Structure of the vicillin buried peptide (VBP) domains of Ana o 1 and Pis v 3 were determined. The NMR structure showed 4 of the cysteine residues are disulfide bonded and hold together two par…
Elizabeth Ottinger · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2023 · $161,896 — TDB has performed a number of repurposing screening efforts and the IND-directed development of GS-441524. The latter included drug metabolism and pharmacokinetic (PK) studies, human PK modeling, toxicology studies, drug product manufacture and formulation studies. TDB scientists are also contributi…
Amy Pate Patterson · CLINICAL CENTER · 2023 — Regarding our research in lipid metabolism, we have demonstrated that SR-BI mediates LDL binding as well as cholesterol ester (CE) and triacylglycerol (TAG) sorting followed by their internalization to LDs. While about 60% of LDL- delivered neutral lipid (NL) to be uploaded to LDs requires neutral h…
T. Jake Liang · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2023 · $2,198,134 — Therapy for hepatitis C virus (HCV) infection has advanced rapidly with the recent approval of several direct-acting antivirals. However, most of the DAAs in clinical use or clinical trials target the same stage of HCV replication cycle and are associated with rapid emergence of drug-resistant viral…
Niraj Tolia · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $291,366 — SARS-CoV-2 is a serious global threat that has been met with an unparalleled research response. Scientific understanding of SARS-CoV-2 is already deeper than most pathogens and it is growing rapidly. This knowledge provides an opportunity to design a vaccine that goes beyond traditional methods. …
Thomas Nutman · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $166,866 — In response to the SARS-CoV-2 pandemic, we leveraged our expertise in human T cell cloning to generate SARS-CoV2-specificT cell lines from naive CD4+ and CD8+ T cells of uninfected (SARS Cov2-naive) individuals. To this end, we generated S-specific, M-specific, CMV-specific (controls), CEF-specific …
Chen-Hsiang Shen · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $157,845 — An understanding of the serum responses of virus-infected individuals and vaccinees is critical for the development of effective vaccines against HIV-1, SARS-CoV-2 and other viral pathogens. Perhaps the most important biological aspect of a serum response is its neutralizing activity, with a close s…
Cheng Cheng · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,325,099 — During the past year, we have created and tested new vaccine candidates, including envelope proteins and fusion peptides displayed carrier as protein immunogens or mRNA vaccines. In addition, we have continued our work testing different methods and routes of administration as well as prime/boost com…
Aleksandra Nita-Lazar · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $99,917 — The focus of the proteomic approach is to identify and quantify viral structural proteins, specifically spike (S) glycoprotein as well as envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein in patient samples. The S protein mediates attachment of the virus to the host cell surfa…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,955,452 — We are developing parainfluenza virus- and pneumovirus-vectored vaccines for intranasal immunization against SARS-CoV-2. These viral vectors are designed to be highly attenuated in humans. They replicate to low levels in the superficial layers of the respiratory epithelium, and are optimized to indu…
Wing Pui Kong · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,480,852 — The Virology Core has collaborated with other intramural NIAID labs help to develop a pan-coronaviruses spike protein subunit vaccine and a re-emerging infectious diseases, EV-D68. During the past year, we focused on developing the vaccine vaccines against most subecoviruses or beta-coronaviruses…
Sanghyun Lee · BROWN UNIVERSITY · 2023 · $168,651 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19). Spike protein is the primary antigenic target for COVID vaccines and interfering with the interface between RBD (Receptor Binding Domain) of spike and ACE2 is the mechanism of …
ALLAN I LEVEY · EMORY UNIVERSITY · 2023 · $848,837 — The Open Drug Discovery Center for AD (Open-AD) Structural Biology core aims to provide Target Enabling Packages (TEPs): a combination of experimental tools and knowledge that will allow researchers to investigate the biology of potential drug targets and to test therapeutic hypotheses. The TEPs wil…
Pamela J Bjorkman · ROCKEFELLER UNIVERSITY · 2023 · $971,500 — Project 3: Summary/Abstract SARS-CoV-2, a newly-emergent betacoronavirus in the sarbecovirus genus, resulted in a global pandemic in 2020, infecting millions and causing COVID-19 disease. Two other zoonotic betacoronaviruses, SARS-CoV (a sarbecovirus) and MERS-CoV (a merbecovirus), also resulted in …
David Scott Wilson · JOHNS HOPKINS UNIVERSITY · 2023 · $245,625 — 1. ABSTRACT/SUMMARY Given that the site of entry of SARS-CoV-2 is the respiratory mucosa, an effective vaccine for SARS-CoV-2 should initiate both humoral and respiratory mucosal immune responses. Although an intranasal subunit vaccine would be an ideal platform for SARS-CoV-2, transport across the …
MICHAEL G ROSENFELD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $400,697 — ABSTRACT Alzheimer’s disease (AD) presents a formidable therapeutic challenge, as current interventions have failed to slow disease progression. The majority of AD genetic risk variants identified by GWAS reside in non- coding regions of the genome, suggesting that alterations in gene expression con…